Characteristics of the studies included and quality scores in the current meta-analysis
| Gene | Polymorphism | Study group (year) | Design | Location | Ethnicity | Treatment | No. of patients | Mean age (years) | Female (%) | Follow-up (months) | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VEGF-A | Rs699947 A>C | Hautam'a'ki (2013) | Prospective | Finland | Caucasian | BVZ | 96 | 78.0 | 63.5 | 4 | 8 |
| Kitchens (2013) | Retrospective | USA | Caucasian | RBZ or BVZ | 99 | 80.0 | 67.3 | 4 | 8 | ||
| Lazzeri (2013) | Prospective | Italy | Caucasian | RBZ | 64 | 76.3 | 45.3 | 9 | 7 | ||
| Park (2014) | Prospective | South Korea | East Asia | RBZ | 270 | 69.5 | 43.6 | 5 | 8 | ||
| Hagstrom (2014) | Prospective | USA | Caucasian | RBZ or BVZ | 835 | 78.5 | 61.2 | 12 | 8 | ||
| Cruz-Gonzalez (2014) | Prospective | Spain | Caucasian | RBZ | 74 | 71.6 | 52.1 | 12 | 8 | ||
| Van Asten (2014) | Prospective | The Netherlands, Germany, Canada | Caucasian | RBZ | 375 | N/A | 56.2 | 3 | 7 | ||
| Rs 699946 A>G | Park (2014) | Prospective | South Korea | East Asia | RBZ | 273 | 69.5 | 43.6 | 5 | 8 | |
| Hagstrom (2014) | Prospective | USA | Caucasian | RBZ or BVZ | 835 | 78.5 | 61.2 | 12 | 8 | ||
| Rs 833069 C>T | Hagstrom (2014) | Prospective | USA | Caucasian | RBZ or BVZ | 835 | 78.5 | 61.2 | 12 | 8 | |
| Van Asten (2014) | Prospective | The Netherlands, Germany, Canada | Caucasian | RBZ | 368 | N/A | 56.2 | 3 | 7 | ||
| Rs 833061 C>T | Kitchens (2013) | Retrospective | USA | Caucasian | RBZ or BVZ | 99 | 80.0 | 67.3 | 4 | 8 | |
| Park (2014) | Prospective | South Korea | East Asia | RBZ | 271 | 69.5 | 43.6 | 5 | 8 | ||
| Cruz-Gonzalez (2014) | Prospective | Spain | Caucasian | RBZ | 74 | 71.6 | 52.1 | 12 | 8 | ||
| Rs 2146323 A>C | Hautam'a'ki (2013) | Prospective | Finland | Caucasian | BVZ | 96 | 78.0 | 63.5 | 4 | 8 | |
| Hagstrom (2014) | Prospective | USA | Caucasian | RBZ or BVZ | 835 | 78.5 | 61.2 | 12 | 8 | ||
| Rs 1413711 T>C | McKibbin (2012) | Prospective | UK | Caucasian | RBZ | 104 | 81.5 | 55.8 | 6 | 7 | |
| Hagstrom (2014) | Prospective | USA | Caucasian | RBZ or BVZ | 835 | 78.5 | 61.2 | 12 | 8 | ||
| Rs 2010963 C>G | Kitchens (2013) | Retrospective | USA | Caucasian | RBZ or BVZ | 99 | 80.0 | 67.3 | 4 | 8 | |
| Hagstrom (2014) | Prospective | USA | Caucasian | RBZ or BVZ | 835 | 78.5 | 61.2 | 12 | 8 | ||
| Rs1570360 G>A | Kitchens (2013) | Retrospective | USA | Caucasian | RBZ or BVZ | 99 | 80.0 | 67.3 | 4 | 8 | |
| Lazzeri (2013) | Prospective | Italy | Caucasian | RBZ | 64 | 76.3 | 45.3 | 9 | 7 | ||
| VEGFR2 | Rs 2071559 A>G | Hagstrom (2014) | Prospective | USA | Caucasian | RBZ or BVZ | 835 | 78.5 | 61.2 | 12 | 8 |
| Cruz-Gonzalez (2014) | Prospective | Spain | Caucasian | RBZ | 74 | 71.6 | 52.1 | 12 | 8 |
BVZ, bevacizumab; RBZ, ranibizumab; VEGF-A, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor.